89459-25-6 | N-[2-(Dimethylamino)ethyl]-4-acridinecarboxamide

Packsize	Purity	Availability	Price	Discounted Price
5mg	98%	1 week	$156.00	$109.00
10mg	98%	1 week	$216.00	$151.00
25mg	98%	1 week	$380.00	$266.00
50mg	98%	1 week	$560.00	$392.00
100mg	98%	1 week	$860.00	$602.00

Description

• Catalog Number: AW53953
• Chemical Name: N-[2-(Dimethylamino)ethyl]-4-acridinecarboxamide
• CAS Number: 89459-25-6
• Molecular Formula: C18H19N3O
• Molecular Weight: 293.363
• MDL Number: MFCD00869683
• SMILES: CN(CCNC(=O)c1cccc2c1nc1ccccc1c2)C

Computed Properties

• Complexity: 385
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 22
• Hydrogen Bond Acceptor Count: 3
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 4
• XLogP3: 3.3

Literature

• Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance.

  Drug metabolism and disposition: the biological fate of chemicals 20120701

• Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers.

  Cell communication and signaling : CCS 20110101

• Intracellular trafficking as a determinant of AS-DACA cytotoxicity in rhabdomyosarcoma cells.

  BMC cell biology 20110101

• Attenuation of cytotoxic natural product DNA intercalating agents by caffeine.

  Scientia pharmaceutica 20110101

• In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase.

  Drug metabolism and disposition: the biological fate of chemicals 20100801

• In vitro assessment of novel transcription inhibitors and topoisomerase poisons in rhabdomyosarcoma cell lines.

  Cancer chemotherapy and pharmacology 20091101

• Early tumor drug pharmacokinetics is influenced by tumor perfusion but not plasma drug exposure.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081215

• The role of topoisomerases and RNA transcription in the action of the antitumour benzonaphthyridine derivative SN 28049.

  Cancer chemotherapy and pharmacology 20081001

• Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma.

  Bioorganic & medicinal chemistry 20080815

• Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes.

  Cancer chemotherapy and pharmacology 20080401

• Inhibition of human CYP1A2 oxidation of 5,6-dimethyl-xanthenone-4-acetic acid by acridines: a molecular modelling study.

  Clinical and experimental pharmacology & physiology 20050801

• Mechanisms of action of DNA intercalating acridine-based drugs: how important are contributions from electron transfer and oxidative stress?

  Current medicinal chemistry 20031201

• Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines.

  Journal of medicinal chemistry 20030313

• Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030115

• Pharmacokinetics of radiolabelled anticancer drugs for positron emission tomography.

  Current pharmaceutical design 20030101

• Inter-strain variability in aldehyde oxidase activity in the mouse.

  Comparative biochemistry and physiology. Toxicology & pharmacology : CBP 20020701

• Kinetic studies of the binding of acridinecarboxamide topoisomerase poisons to DNA: implications for mode of binding of ligands with uncharged chromophores.

  Journal of medicinal chemistry 20020214

• Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).

  Anti-cancer drug design 20011201

• Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes.

  British journal of clinical pharmacology 20010801

• Extravascular transport of the DNA intercalator and topoisomerase poison N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide (DACA): diffusion and metabolism in multicellular layers of tumor cells.

  The Journal of pharmacology and experimental therapeutics 20010601

• Comparative biodistribution and metabolism of carbon-11-labeled N-[2-(dimethylamino)ethyl]acridine-4-carboxamide and DNA-intercalating analogues.

  Cancer research 20010401

• Individual variation in hepatic aldehyde oxidase activity.

  IUBMB life 20010401

• Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in patients by positron emission tomography.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010301

• Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs.

  Cancer chemotherapy and pharmacology 20000101